Sarah Whitcombe specialises in medical, pharmaceutical, and public health controversies with a focus on regulatory failures.
We investigate how market incentives, regulation and manufacturing fragility contribute to drug shortages and fuel controversy around Big Pharma.
We have been tracking drug shortages for years and we know they are complex. Shortages hit hospitals, clinics and families and they expose weak spots in global supply chains. In this piece we separate peer reviewed research, expert commentary and informed speculation so readers can see what is well supported and what remains contested. We draw on reports from the US Food and Drug Administration, the World Health Organization and public auditors, alongside researchers such as Dr Erin Fox, to map incentives that shape what gets made and when supply fails.
What is driving shortages?
We start with the basics. Drug shortages arise when demand outstrips supply or when production is interrupted. Causes range from quality problems in factories to raw material scarcity to sudden spikes in clinical need. The US Food and Drug Administration maintains a live Drug Shortages page that documents ongoing shortages and often lists withdrawals for manufacturing reasons. These disruptions are not always the result of malice or conspiracy. They are frequently the product of fragile, globalised production chains and lean inventory practices.
How market incentives shape supply
Our team sees a pattern where low profitability and high regulatory cost push manufacturers away from older generics and injectables. Where profit margins are thin, companies have less incentive to invest in redundant capacity or rapid repairs when trouble hits. The World Health Organization has repeatedly warned that market failures can make essential medicines vulnerable. In plain terms, when making a product costs more than the expected return, fewer companies remain in that market. That reduced competition increases the risk of shortages.
Peer reviewed research
Peer reviewed work has quantified parts of this picture. Studies published in clinical and pharmaceutical journals document associations between manufacturing problems and shortages. Academic analyses often point to consolidation in supply chains and a drop in the number of manufacturers for certain sterile injectables as key drivers. We cite these findings as the best empirical evidence that economic structure and technical fragility can produce persistent shortages.
Expert opinion
Experts such as Dr Erin R Fox, formerly of the University of Utah Drug Information Service, have provided extensive commentary on the practical causes of shortages and mitigation strategies. Public audit bodies like the US Government Accountability Office have issued reports linking quality lapses, supply concentration and transparency gaps to shortages. These voices help interpret the data and recommend policy fixes such as stockpiles, early warning systems and incentives to sustain low margin drugs.
Where we cross into speculation
We are careful to separate evidence from speculation. It is tempting to assume deliberate withholding or collusion when lifesaving medicines become scarce. While isolated bad actors may exist, most convincing analyses point to structural incentives rather than coordinated conspiracies. That said, opaque contracting, non-transparent supply deals and pricing strategies can appear suspicious to communities left without access. We flag these as areas where further investigation and whistleblower disclosures could be informative.
What to watch next
Policy responses matter. Regulatory steps that improve factory oversight and transparency can reduce quality related stoppages. Financial incentives such as minimum purchase guarantees for essential generics are being debated in several jurisdictions. We watch how regulators balance encouraging resilient supply chains with incentives that avoid simply subsidising inefficiency.
In closing we present evidence and cautious interpretation, and we invite readers to scrutinise both official accounts and industry narratives.
References and sources
Sign up to our newsletter for daily briefs.
